8. O'Reilly A, Murphy J, Rawe S, Garvey M. Chronic Lymphocytic Leukemia: A Review of Front-line Treatment Options, With a Focus on Elderly CLL
Patients. Clin Lymphoma Myeloma Leuk 2018; 18(4): 249-256.
9. Eketorp Sylvan S, Lundin J, Ipek M, Palma M, Karlsson C, Hansson L.
Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL)-a single region experience on consecutive patients. Annals of hematology 2014;
93(10): 1725-1733.
10. Mihalyova J, Jelinek T, Growkova K, Hrdinka M, Simicek M, Hajek R.
Venetoclax: A new wave in hematooncology. Exp Hematol 2018; 61: 10-25.
11. NCCN Clinical Practice Guideline in Oncology - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf.
Published 2018. Accessed May 17, 2018.
12. WHOCC-ATC/DDD Index. WHO Collaborating Centre for Drug Statistics Methodology. https://www.whocc.no/atc_ddd_index/?code=L01XX52.
Published 2017. Accessed May 18, 2018.
13. 西藥、醫療器材、含藥化粧品許可證查詢. 衛生福利部食品藥物管理署.
https://www.fda.gov.tw/MLMS/H0001.aspx. Published 2018. Accessed May 18, 2018.
14. 全民健康保險藥品給付規定. 行政院衛生福利部中央健康保險署.
https://www.nhi.gov.tw/Content_List.aspx?n=E70D4F1BD029DC37&topn=3
FC7D09599D25979. Published 2017. Accessed May 21, 2018.
15. Venclexta for Chronic Lymphocytic Leukemia (with 17p deletion) - Details.
Canadian Agency for Drugs and Technologies in Health.
https://www.cadth.ca/venclexta-chronic-lymphocytic-leukemia-17p-deletion-d
etails. Published 2016. Accessed May 8, 2018.
16. Committee PBA. Public Summary Document - March 2017 PBAC Meeting.
5.09 VENETOCLAX, Tablet 10 mg, 50 mg and 100 mg, Venclexta® , AbbVie Pty Ltd.
<http://www.pbs.gov.au/pbs/industry/listing/elements/pbac-meetings/psd/2017
-03/venetoclax-psd-march-2017>. Published 2017. Accessed May 8, 2018.
17. Committee PBA. Public Summary Document - July 2017 PBAC Meeting.
4.06 VENETOCLAX Tablet 10 mg, 50 mg and 100 mg, Venclexta® , AbbVie Pty Ltd. Pharmaceutical Benefits Scheme, Department of Health,
Commonwealth of Australia.
<http://www.pbs.gov.au/pbs/industry/listing/elements/pbac-meetings/psd/2017
-07/venetoclax-psd-july-2017>. Published 2017. Accessed May 8, 2018.
18. Committee PBA. Public Summary Document - November 2017 PBAC
Meeting. 7.16 VENETOCLAX Tablet 10 mg, 50 mg and 100 mg, Venclexta® , AbbVie Pty Ltd. Pharmaceutical Benefits Scheme, Department of Health, Commonwealth of Australia.
<http://www.pbs.gov.au/pbs/industry/listing/elements/pbac-meetings/psd/2017
-11/venetoclax-psd-november-2017>. Published 2017. Accessed May 8, 2018.
19. Venetoclax for treating chronic lymphocytic leukaemia. National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ta487.
Published 2017. Accessed May 8, 2018.
20. Venetoclax, 10mg, 50mg and 100mg film-coated tablets (Venclyxto
®
) SMC No. (1249/17). Scottish Medicines Consortium.
https://www.scottishmedicines.org.uk/medicines-advice/venetoclax-venclyxto-fullsubmission-124917/. Published 2017. Accessed May 8, 2018.
21. Venclyxto: EPAR-Public assessment report. European Medicines Agency.
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medici nes/004106/human_med_002045.jsp&mid=WC0b01ac058001d124. Published
2016. Accessed May 25, 2018.22. Clinical Pharmacology Biopharmaceutics Review(s)-venetoclax. U.S. Food and Drug Administration.
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208573Orig1s000T
OC.cfm. Published 2016. Accessed May 25, 2018.
23. Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol 2016; 17(6): 768-778.
24. Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J Clin Oncol 2018: Jco2017766840.
25. Alsaid N, McBride A, Oh M, et al. Economic evaluation for the US of venetoclax versus allogeneic hematopoietic stem-cell transplantation for patients with relapsed or refractory chronic lymphocytic leukemia with 17p deletion. Blood 2017; 130.
26. Djambazov S, Veleva N, Tsanova D, Vekov T. Cost-effectiveness analysis of venetoclax for treatment of refractory/relapsed chronic lymphocytic leukemia with or without 17p deletion in Bulgaria. Value in Health 2017; 20(9): A754.
27. 衛生福利部國民健康署. 中華民國 99 年癌症登記年報. Published 2013.
Accessed May. 16th, 2018.
28. 衛生福利部國民健康署. 中華民國 101 年癌症登記年報. Published 2015.
Accessed May. 16th, 2018.
29. 衛生福利部國民健康署. 中華民國 100 年癌症登記年報. Published 2014.
Accessed May. 16th, 2018.
30. 衛生福利部國民健康署. 中華民國 102 年癌症登記年報 Published 2016.
Accessed May. 16th, 2018.
31. 衛生福利部國民健康署. 中華民國 103 年癌症登記報告. Published 2017.
Accessed May. 16th, 2018.
32. Tam CS, Stilgenbauer S. How best to manage patients with chronic
lymphocytic leuekmia with 17p deletion and/or TP53 mutation? Leukemia &
lymphoma 2015; 56(3): 587-593.
33. Wu SJ, Lin CT, Huang SY, et al. Chromosomal abnormalities by conventional cytogenetics and interphase fluorescence in situ hybridization in chronic lymphocytic leukemia in Taiwan, an area with low incidence--clinical implication and comparison between the West and the East. Annals of
hematology 2013; 92(6): 799-806.
34. Wu S-J, Lin C-T, Agathangelidis A, et al. Distinct molecular genetics of chronic lymphocytic leukemia in Taiwan: clinical and pathogenetic implications. Haematologica 2017; 102(6): 1085-1090.
35. 衛生福利部統計處. 105 年度全民健康保險醫療統計年報
https://dep.mohw.gov.tw/DOS/np-3733-113.html. Published 2017. Accessed May.29th, 2018.
36. 衛生福利部中央健康保險署-癌症費用排行. 105 年各類癌症健保前 10 大 醫療支出統計.
https://www.nhi.gov.tw/Content_List.aspx?n=AE8F3C1B6EC35217&topn=C
DA985A80C0DE710. Published 2017. Accessed May.29th, 2018.
37. Rozovski U, Harris D, Li P, et al. CLL and Fat Cells Utilize Similar Metabolic Pathways. Clinical Lymphoma, Myeloma and Leukemia 2017; 17: S303-S304.
附錄
附錄一 療效電子資料庫搜尋記錄 Cochrane Library
查詢日期 編
號 關鍵字 篇數
2018/05/25
#1 MeSH descriptor: [Leukemia, Lymphocytic, Chronic,
B-Cell] explode all tree 314
#2 Chronic lymphocytic leukemia 1,170
#3 #1 or #2 1,170
#4 venetoclax 100
#5 "ABT-199" or "GDC-0199" 19
#6 #4 or #5 102
#7 #3 and #6 42
PubMed
查詢日期 編
號 關鍵字 篇數
2018/05/25 #1 "Chronic lymphocytic leukemia"[All Fields] 14,792
#2 "leukemia, lymphocytic, chronic, b-cell"[MeSH Terms] 14,609
#3 #1 OR #2 20,241
#4 "venetoclax"[Supplementary Concept] OR
"venetoclax"[All Fields] 401
#5
("venetoclax"[Supplementary Concept] OR
"venetoclax"[All Fields] OR "abt 199"[All Fields]) OR ("venetoclax"[Supplementary Concept] OR
"venetoclax"[All Fields] OR "gdc 0199"[All Fields])
482
#6 #3 AND #5 201
#7
(("venetoclax"[Supplementary Concept] OR
"venetoclax"[All Fields] OR "abt 199"[All Fields]) OR ("venetoclax"[Supplementary Concept] OR
"venetoclax"[All Fields] OR "gdc 0199"[All Fields])) AND ("leukemia, lymphocytic, chronic, b-cell"[MeSH Terms] OR "Chronic lymphocytic leukemia"[All Fields]) AND Clinical Trial[ptyp]
14
#8 (("venetoclax"[Supplementary Concept] OR
"venetoclax"[All Fields] OR "abt 199"[All Fields]) OR 1
("venetoclax"[Supplementary Concept] OR
"venetoclax"[All Fields] OR "gdc 0199"[All Fields])) AND ("leukemia, lymphocytic, chronic, b-cell"[MeSH Terms] OR "Chronic lymphocytic leukemia"[All Fields]) AND Randomized Controlled Trial[ptyp]
#9
(("venetoclax"[Supplementary Concept] OR
"venetoclax"[All Fields] OR "abt 199"[All Fields]) OR ("venetoclax"[Supplementary Concept] OR
"venetoclax"[All Fields] OR "gdc 0199"[All Fields])) AND ("leukemia, lymphocytic, chronic, b-cell"[MeSH Terms] OR "Chronic lymphocytic leukemia"[All Fields]) AND systematic[sb]
11
#10
(("venetoclax"[Supplementary Concept] OR
"venetoclax"[All Fields] OR "abt 199"[All Fields]) OR ("venetoclax"[Supplementary Concept] OR
"venetoclax"[All Fields] OR "gdc 0199"[All Fields])) AND ("leukemia, lymphocytic, chronic, b-cell"[MeSH Terms] OR "Chronic lymphocytic leukemia"[All Fields]) AND Meta-Analysis[ptyp]
1
#11 #7 OR #8 OR #9 OR #10 25 Embase
2018/05/25
#1 'chronic lymphatic leukemia'/exp OR 'chronic lymphatic
leukemia' 39,517
#2 'venetoclax' 1,465
#3 #1 AND #2 569
#4
#1 AND #2 AND ([cochrane review]/lim OR [systematic review]/lim OR [meta analysis]/lim OR [controlled clinical trial]/lim OR [randomized controlled trial]/lim)
77
附錄二 經濟評估文獻搜尋記錄
資料庫 查詢日期 關鍵字 篇數 篩 選
後 篇 數 Pubmed 2018.05.18 #1 venetoclax
#2 chronic lymphocytic leukaemia
#3 (((cost-effectiveness analysis) OR cost-utility analysis) OR cost-benefit analysis) OR cost-minimization analysis
#1 AND #2 AND #3
3 0
EMBASE 2018.05.18 #1 venetoclax
#2 chronic lymphocytic leukaemia
#3 Economic evaluation
#1 AND #2 AND #3
3 2